All good & it’s actually really good news. I am hopeful that before a Ph3 happens for AD with Xanamem that the FDA will come on board with Accelerated Approval. It’s such a clinically unmet need globally, not just a diagnosis of AD but cognitive impairment in older people also & MH.
We know the huge benefits of both being an oral drug (more accessible to patients & QOL & care for them vs infusions in a hospital/outpatient setting plus the cost) as well as safety data. I know there is more happening in the AD space, but just WOW on the Biogen nightmare & patients dying on clinical trials from cerebral haemorrhage.
As you would have read, ILAP Passport is there for good reason, so congratulations to Dr Gourlay & team for securing this. Both NICE & MRHA are involved in granting this, so it’s already a good sign.
Beats old misery guts & his scotch saying he has no confidence lol! All that crap got put to bed long ago, with biomarkers for AD recently developed & doses…just salty & probably needs to drop a bit of Xanamem in his Scotch himself if he can’t see that the likes of NICE & KOL have found Xanamem & ACW to be worthy of an ILAP Passport.
Good to see you are still here Thymus.
ACW Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held
